FDA Backs Lurbinectedin + Atezolizumab for ES-SCLC Care FDA approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) with atezolizumab (Tecentriq, Genentech) or atezolizumab…
Browsing: FDA
The FDA approved INLEXZO™ / gemcitabine intravesical on September 9, 2025, to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with…
Introduction to Datopotamab Deruxtecan EGFR-Mutated NSCLC On June 23, 2025, the FDA approved Datopotamab Deruxtecan EGFR-Mutated NSCLC treatment, known as…
FDA Voucher Program Oncology: Accelerated Approvals in Oncology On June 17, 2025, the FDA launched the Commissioner’s National Priority Voucher…